Clinical trial · Interventional
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
NCT01263899CI-TRIAL-00006759completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Indolent Lymphoma | Indolent Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SB1518 | Drug | Pacritinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SB1518
- interventionNames
- Drug: SB1518
Primary outcomes (1)
- measure
- Assess overall tumor response of SB1518 by CT/FDG-PET scan and bone marrow biopsy as applicable as a measure of efficacy
- timeFrame
- Every even numbered cycle from baseline to 30 days after the last dose of study medication
- description
- Outcome Measure - To assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphophasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).
Secondary outcomes (2)
- measure
- Assess durability of response
- timeFrame
- Every even numbered cycle from baseline to 30 days after the last dose of study medication
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically documented diagnosis of one of the following lymphoid malignancies: * Hodgkin Lymphoma; * Mantle Cell Lymphoma; * Indolent Lymphoma (including follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma); * Patients must have received at least one prior treatment regimen; patients with Hodgkin Lymphoma must have received an autologous stem cell transplant, refused or been deemed ineligible for stem cell transplant; * Able to understand and willing to sign the informed consent form. Exclusion Criteria: * Any histology other than Hodgkin Lymphoma, Mantle Cell Lymphoma or Indolent Lymphoma; * History of or active Central Nervous System (CNS) malignancy; * Active graft-versus-host disease (GVHD);
References
Publications (0)
Data not yet available
No reference posted for this study.